Ningbo Menovo Pharm Co Ltd
Ningbo Menovo Pharmaceutical Co., Ltd. research, develops, produces, and sells pharmaceutical products. The company's products portfolio includes valsartan, losartan, clopidogrel, perindopril, rosuvastatin calcium, atorvastatin calcium, purin bahrain, and other products. It offers APIs, intermediates, and preparations for the treatment of cardiovascular, central nervous system, gastrointestinal t… Read more
Ningbo Menovo Pharm Co Ltd (603538) - Total Liabilities
Latest total liabilities as of September 2025: CN¥2.33 Billion CNY
Based on the latest financial reports, Ningbo Menovo Pharm Co Ltd (603538) has total liabilities worth CN¥2.33 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Ningbo Menovo Pharm Co Ltd - Total Liabilities Trend (2011–2024)
This chart illustrates how Ningbo Menovo Pharm Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Ningbo Menovo Pharm Co Ltd Competitors by Total Liabilities
The table below lists competitors of Ningbo Menovo Pharm Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kimball Electronics
NASDAQ:KE
|
USA | $504.31 Million |
|
Heiwa Corporation
F:HWC
|
Germany | €845.09 Billion |
|
Shenzhen Urovo Technology Co Ltd
SHE:300531
|
China | CN¥720.47 Million |
|
Sarkuysan Elektrolitik Bakir Sanayi ve Ticaret AS
IS:SARKY
|
Turkey | TL13.79 Billion |
|
Metropolis Healthcare Limited
NSE:METROPOLIS
|
India | ₹5.49 Billion |
|
Genesis Energy Limited
F:1G6
|
Germany | €3.13 Billion |
|
Advanced Wireless Semiconductor Co
TWO:8086
|
Taiwan | NT$2.29 Billion |
|
Argan SA
PA:ARG
|
France | €1.97 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Ningbo Menovo Pharm Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.28 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.49 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ningbo Menovo Pharm Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ningbo Menovo Pharm Co Ltd (2011–2024)
The table below shows the annual total liabilities of Ningbo Menovo Pharm Co Ltd from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥2.36 Billion | +5.45% |
| 2023-12-31 | CN¥2.24 Billion | -0.37% |
| 2022-12-31 | CN¥2.25 Billion | +11.03% |
| 2021-12-31 | CN¥2.02 Billion | +55.59% |
| 2020-12-31 | CN¥1.30 Billion | +24.37% |
| 2019-12-31 | CN¥1.05 Billion | +12.30% |
| 2018-12-31 | CN¥930.92 Million | +165.08% |
| 2017-12-31 | CN¥351.19 Million | +56.59% |
| 2016-12-31 | CN¥224.27 Million | +23.34% |
| 2015-12-31 | CN¥181.83 Million | -54.83% |
| 2014-12-31 | CN¥402.54 Million | +6.71% |
| 2013-12-31 | CN¥377.24 Million | -3.02% |
| 2012-12-31 | CN¥389.00 Million | +17.35% |
| 2011-12-31 | CN¥331.50 Million | -- |